Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
canakinumab + spartalizumab
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Canakinumab + spartalizumab is an investigational combination therapy consisting of two monoclonal antibodies developed by Novartis. Canakinumab is a high-affinity human monoclonal antibody targeting interleukin-1 beta (IL-1β), neutralizing its inflammatory activity and thereby reducing inflammation. Spartalizumab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, acting as an immune checkpoint inhibitor to enhance T-cell mediated antitumor responses. This combination has been studied in early-phase clinical trials for various cancers, including metastatic pancreatic cancer and localized clear cell renal cell carcinoma, with the aim of leveraging both anti-inflammatory and immunomodulatory mechanisms to improve antitumor efficacy[2][3][4][5][7].
- Brand names
- Ilaris
- Other names
- spartalizumab + canakinumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on canakinumab + spartalizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on canakinumab + spartalizumab.